Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine.
Efficacy against hospitalisation for Sinovac in Chile, Brazil and Turkey was , respectively.
In Brazil, the immunizing agent against covid-19 is authorized only for those over 18 years of age.
The results indicate that a third of CoronaVac® induces a strong immune response in healthy adults with no serious adverse reactions related to the vaccine.
In addition, an article published by the journal on June 4, 2021, stated: "CoronaVac will significantly contribute to the global fight against COVID-19 as a safe and moderately effective SARS-CoV-2 vaccine," says.
The vaccines contain many proteins the immune system can respond to, stimulating the production of antibodies to fight COVID-19.